Table 1 In vitro anticancer screening results of compounds 2, 4, 5, (7–10) and (12–16) against sixty human tumour cell lines with single dose assay (10–5 M concentration). Data was provided as cell growth inhibition percentage.
Subpanel/tumour cell lines | Compoundsa | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 4 | 5 | 7 | 8 | 9 | 10 | 12 | 13 | 14 | 15 | 16 | |
Leukemia | ||||||||||||
CCRF-CEM | – | – | – | – | – | – | – | – | – | – | – | – |
HL-60(TB) | – | – | – | – | – | – | – | – | – | – | – | – |
K-562 | – | 12.50 | – | 19.06 | 11.47 | – | – | – | – | – | – | – |
MOLT-4 | – | – | – | – | – | – | – | – | – | – | – | – |
RPMI-8226 | – | 22.45 | 13.43 | 11.43 | 29.42 | 51.58 | – | – | – | – | – | – |
SR | – | – | – | 9.30 | – | – | – | – | – | – | – | – |
Non-small cell lung cancer | ||||||||||||
A549/ATCC | – | – | – | – | – | – | – | – | – | – | – | – |
EKVX | – | – | – | – | – | – | 16.39 | – | – | – | – | – |
HOP-62 | 16.88 | 23.38 | 12.88 | 30.19 | 29.39 | 20.17 | 22.28 | 18.57 | 13.10 | 14.43 | 16.16 | 22.80 |
HOP-92 | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT |
NCI-H226 | – | – | – | – | – | 11.58 | – | – | – | – | – | – |
NCI-H23 | – | – | – | – | – | – | – | – | – | – | – | – |
NCI-H322M | – | – | – | 8.09 | – | – | – | – | – | – | – | – |
NCI-H460 | – | – | – | – | – | – | – | – | – | – | – | – |
NCI-H522 | 10.14 | 19.05 | 13.32 | 16.19 | 24.14 | 12.55 | 8.83 | 10.63 | – | – | – | – |
Colon cancer | ||||||||||||
COLO 205 | – | – | – | – | – | – | – | – | – | – | – | – |
HCC-2998 | – | – | – | – | – | – | – | – | – | – | – | – |
HCT-116 | – | 9.85 | – | – | 14.71 | 77.94 | – | – | – | – | – | – |
HCT-15 | – | – | – | – | – | – | – | – | – | – | – | – |
HT29 | – | – | – | – | – | – | – | – | – | – | – | – |
KM12 | – | – | – | – | 10.42 | - | – | – | – | – | – | – |
SW-620 | – | – | – | – | – | 8.07 | – | – | – | – | – | – |
CNS cancer | ||||||||||||
SF-268 | – | – | – | – | – | – | – | – | – | – | – | – |
SF-295 | – | – | – | – | 14.91 | 9.57 | – | – | – | – | – | – |
SF-539 | – | – | – | – | – | – | – | – | – | – | – | – |
SNB-19 | – | 10.40 | 8.87 | 8.94 | 14.40 | 12.79 | – | – | – | – | – | – |
SNB-75 | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT |
U251 | – | – | – | – | – | 9.37 | – | – | – | – | – | – |
Melanoma | ||||||||||||
LOX IMVI | – | – | – | 8.68 | – | 8.76 | – | – | – | – | – | – |
MALME-3M | – | – | 9.41 | – | 14.76 | – | 16.30 | – | – | – | – | 8.69 |
M14 | – | – | – | – | – | – | – | – | – | – | – | – |
MDA-MB-435 | – | – | – | – | – | – | – | – | – | – | – | – |
SK-MEL-2 | – | – | – | – | – | – | – | – | – | – | – | – |
SK-MEL-28 | – | – | – | – | – | – | – | – | – | – | – | – |
SK-MEL-5 | – | – | – | – | – | – | – | – | – | – | – | – |
UACC-257 | – | – | – | – | 9.97 | – | – | – | – | – | – | – |
UACC-62 | – | 21.71 | – | 22.82 | 28.57 | 19.56 | 12.73 | – | – | – | – | 9.64 |
Ovarian cancer | ||||||||||||
IGROV1 | – | 15.09 | – | – | – | 10.62 | – | – | – | – | – | – |
OVCAR-3 | – | – | – | – | – | – | – | – | – | – | – | – |
OVCAR-4 | – | 9.96 | – | – | 13.10 | – | – | – | – | – | – | – |
OVCAR-5 | – | – | – | – | – | – | – | – | – | – | – | – |
OVCAR-8 | – | – | – | – | – | – | – | – | – | – | – | – |
NCI/ADR-RES | – | – | – | – | – | – | – | – | – | – | – | – |
SK-OV-3 | – | 8.53 | – | 11.98 | 36.25 | 12.68 | 13.42 | 10.36 | – | – | – | 17.88 |
Renal cancer | ||||||||||||
786-0 | – | – | – | – | – | – | – | – | – | – | – | – |
A498 | – | – | – | – | – | – | – | – | – | – | – | – |
ACHN | – | 8.16 | – | – | – | – | – | – | – | – | – | – |
CAKI-1 | – | 16.21 | – | 16.91 | 16.39 | 16.77 | 13.41 | – | – | – | – | 15.57 |
RXF 393 | – | – | – | – | – | – | – | – | – | – | – | – |
SN12C | – | – | – | – | – | – | – | – | – | – | – | – |
TK-10 | 13.75 | – | – | – | – | – | – | – | – | – | 9.11 | - |
UO-31 | 9.31 | 32.07 | 24.74 | 28.36 | 24.10 | 36.84 | 34.48 | 25.30 | 10.78 | 8.76 | 9.83 | 27.71 |
Prostate cancer | ||||||||||||
PC-3 | – | 8.83 | – | 21.02 | 23.28 | 9.91 | – | – | – | – | – | 18.14 |
DU-145 | – | – | – | – | – | – | – | – | – | – | – | – |
Breast cancer | ||||||||||||
MCF7 | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT |
MDA-MB- 231/ATCC | – | 13.08 | – | 15.43 | 13.78 | 15.35 | 17.01 | – | – | – | – | 10.11 |
HS 578 T | – | – | – | – | 8.14 | 9.27 | 13.16 | – | – | – | – | – |
BT-549 | – | – | – | – | – | – | – | – | – | – | – | 11.22 |
T-47D | – | 32.30 | 9.75 | 28.31 | 18.61 | 19.37 | 12.09 | – | – | – | – | 15.02 |
MDA-MB-468 | – | – | – | – | – | – | – | – | – | – | – | – |
